David Miller is currently the VP of Drug Discovery at Pathios Therapeutics, where they focus on identifying novel small-molecule modulators of GPR65. Previously, they held the position of Head of Medicinal Chemistry at Inflazome Ltd from 2016 to 2020, and have extensive experience in various leadership roles within the pharmaceutical industry, including positions at Takeda Cambridge and Paradigm Therapeutics Ltd. David's educational background includes a degree from The University of Hull, completed from 1989 to 1992. They are also serving as the Chief Scientific Officer at Melio Bio since 2024.
This person is not in the org chart
This person is not in any teams
This person is not in any offices